{"gene":"SH3BP2","run_date":"2026-04-28T20:42:07","timeline":{"discoveries":[{"year":2001,"finding":"Missense mutations in SH3BP2 (an SH3-binding adaptor protein with SH2, SH3-binding, and pleckstrin homology domains) cause cherubism, identifying SH3BP2 as the disease gene on chromosome 4p16.3","method":"Direct DNA sequencing of affected families; identification of seven mutations in exon 9","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — original disease-gene identification replicated across multiple families and labs","pmids":["11381256"],"is_preprint":false},{"year":2002,"finding":"14-3-3 chaperone proteins physically interact with SH3BP2 in a phosphorylation-dependent manner; PKC-mediated phosphorylation of SH3BP2 at Ser225 and Ser277 is required for 14-3-3 binding, and this interaction negatively regulates SH3BP2-dependent NFAT/AP-1 transcriptional activity in lymphocytes","method":"Yeast two-hybrid, co-immunoprecipitation, alkaline phosphatase dephosphorylation, in vitro PKC kinase assay, deletion/point mutagenesis, NFAT luciferase reporter assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal methods including in vitro kinase assay, mutagenesis, and functional reporter assay in single study","pmids":["12501243"],"is_preprint":false},{"year":2006,"finding":"Cherubism-associated exon 9 missense mutations in SH3BP2 (R415Q, D419N, D420E, P418R) are gain-of-function mutations that increase NFAT transcriptional activity, indicating that cherubism results from gain-of-function SH3BP2 mutations acting through NFAT activation","method":"Transient transfection of mutant SH3BP2 constructs in cells with NFAT luciferase reporter assay","journal":"Human mutation","confidence":"Medium","confidence_rationale":"Tier 2 — functional gain-of-function assay with multiple mutants, single lab","pmids":["16786512"],"is_preprint":false},{"year":2007,"finding":"SH3BP2 cherubism knock-in mice (P416R) exhibit TNF-α-dependent systemic inflammation and bone loss; mutant myeloid cells show increased ERK1/2 and SYK phosphorylation/activation upon M-CSF and RANKL stimulation, forming macrophages with elevated TNF-α and unusually large osteoclasts; the phenotype is lymphocyte-independent and transferable via fetal liver cells, establishing SH3BP2 as a gain-of-function regulator of myeloid cell responses","method":"Knock-in mouse model, bone marrow/fetal liver transplantation, phospho-Western blotting (ERK1/2, SYK), osteoclast differentiation assays, TNF-α measurement, M-CSF/RANKL stimulation experiments","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — rigorous in vivo genetic model with multiple orthogonal mechanistic readouts, highly cited foundational paper","pmids":["17218256"],"is_preprint":false},{"year":2008,"finding":"SH3BP2 overexpression in RAW 264.7 pre-osteoclast cells increases nuclear NFATc1 translocation, TRAP expression, and potentiates sRANKL-stimulated phosphorylation of PLCγ1 and PLCγ2, placing SH3BP2 upstream of PLCγ-calcineurin-NFATc1 in RANKL-induced osteoclastogenesis","method":"Overexpression of SH3BP2 in RAW264.7 cells, Western blotting for phospho-PLCγ1/2 and nuclear NFATc1, TRAP staining as osteoclast differentiation marker","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — defined mechanistic pathway in cell-based assays, single lab","pmids":["18440306"],"is_preprint":false},{"year":2010,"finding":"Mutant SH3BP2 (cherubism mutations) stimulates RANKL-induced PLCγ1/2 phosphorylation more potently than wild-type SH3BP2, resulting in greater NFAT activity and TRAP expression; gain-of-function mechanism operates through the PLCγ-calcineurin-NFAT axis","method":"Transfection of wild-type vs. mutant SH3BP2 in RAW264.7 cells, NFAT-luciferase reporter assay, phospho-PLCγ Western blotting, TRAP assay","journal":"Journal of orthopaedic research","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic pathway defined with multiple readouts, single lab replicating earlier finding","pmids":["20872577"],"is_preprint":false},{"year":2010,"finding":"SH3BP2 is required for normal osteoblast differentiation and function; the P416R cherubism knock-in mutation reduces mature osteoblast numbers, decreases mineral content and crystallinity in bone, and impairs osteoblast-specific gene expression and mineralization in calvarial cultures","method":"Knock-in mouse model, FTIRI spectroscopy of bone, GFP-reporter transgenic cross for osteoblast counting, hematopoietic cell-depleted calvarial osteoblast cultures, gene expression analysis, co-culture osteoclastogenesis assay","journal":"Bone","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (spectroscopy, cell culture, transgenic reporter, co-culture) in single study","pmids":["20117257"],"is_preprint":false},{"year":2011,"finding":"shRNA knockdown of SH3BP2 decreases PLCγ2 phosphorylation and NFATc1 expression, reduces osteoclast number, size, and TRAP staining, and dramatically blocks bone resorptive activity; Sh3bp2-/- BMMs form smaller osteoclasts with reduced TRAP staining, demonstrating SH3BP2 is necessary for osteoclast differentiation and function","method":"shRNA knockdown in RAW264.7 cells and BMMs, phospho-PLCγ2 Western blotting, NFATc1 expression analysis, TRAP staining, bone resorption pit assay, Sh3bp2-/- mouse BMM cultures","journal":"Journal of orthopaedic research","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function with defined molecular phenotype replicated in both knockdown and knockout cells with multiple readouts","pmids":["21448930"],"is_preprint":false},{"year":2011,"finding":"Tankyrase (PARP5) interacts with SH3BP2 and marks it for degradation; cherubism mutations in SH3BP2 disrupt the tankyrase-SH3BP2 interaction, leading to SH3BP2 stabilization (gain-of-function)","method":"Referenced as described in Guettler et al. and Levaot et al. in the same Cell issue (commentary paper)","journal":"Cell","confidence":"Medium","confidence_rationale":"Tier 2 — described via commentary citing two primary papers in same issue; mechanistic claim well established but this entry is a review/preview","pmids":["22153068"],"is_preprint":false},{"year":2012,"finding":"PARP1 binds to a specific element (-44 to -21) in the SH3BP2 promoter and is required for SH3BP2 transcriptional expression; mutagenesis of the PARP1 binding site abolishes SH3BP2 promoter activity, and Parp1 knockout reduces SH3BP2 expression in BMMs","method":"Promoter deletion analysis, streptavidin-biotin DNA pulldown, EMSA, ChIP assay, Parp1 knockout mouse BMMs, luciferase reporter","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 — in vitro EMSA and in vivo ChIP with mutagenesis and genetic knockout validation","pmids":["22820184"],"is_preprint":false},{"year":2014,"finding":"The P416R SH3BP2 cherubism mutation enables TNF-α-induced osteoclastogenesis independently of RANKL, through a mechanism involving SYK and PLCγ2 phosphorylation leading to increased NFATc1 nuclear translocation; SH3BP2 knockdown in RAW264.7 cells reduces TNF-α-induced osteoclastogenesis","method":"BMM differentiation assays from heterozygous knock-in mice with TNF-α, phospho-SYK/PLCγ2 Western blotting, NFATc1 nuclear translocation assay, calvarial TNF-α injection model, human TNF-α transgenic mouse model, shRNA knockdown","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 — multiple in vitro and in vivo models with defined molecular mechanism across multiple readouts","pmids":["24916406"],"is_preprint":false},{"year":2014,"finding":"SH3BP2 gain-of-function (P416R) augments inflammation and bone loss in collagen-induced arthritis through increased macrophage TNF-α production and enhanced RANKL-induced osteoclastogenesis with increased NFATc1 nuclear localization; lymphocyte responses are not significantly affected","method":"CIA model in Sh3bp2 KI/+ mice, histological joint analysis, micro-CT bone loss quantification, cytokine gene expression, BMM TNF-α production, NFATc1 immunostaining, lymph node proliferation assay, serum antibody measurement","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 2 — epistatic in vivo model with multiple orthogonal mechanistic readouts confirming myeloid-cell-specific mechanism","pmids":["25144740"],"is_preprint":false},{"year":2019,"finding":"Tankyrase (PARP5) catalyzes ADP-ribosylation of SH3BP2 targeting it for proteasomal degradation; pharmacological tankyrase inhibition in mice causes SH3BP2 accumulation leading to increased osteoclast formation and bone loss","method":"Tankyrase inhibitor treatment in mice, bone phenotype analysis, SH3BP2 protein level measurement (reviewed mechanistic pathway)","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo pharmacological evidence linking tankyrase activity to SH3BP2 stability and bone loss, review summarizing primary data","pmids":["30813388"],"is_preprint":false},{"year":2019,"finding":"SH3BP2-SYK signaling axis in osteoclasts controls alveolar bone resorption function (rather than osteoclast differentiation) in periodontitis; conditional knockout of SH3BP2 and SYK in myeloid cells (LysM-Cre) reduces alveolar bone loss without affecting inflammatory cytokine expression or osteoclast number","method":"Sh3bp2-/- mouse ligature-induced periodontitis model, micro-CT bone loss analysis, conditional myeloid-specific knockout (LysM-Cre), SYK inhibitor (GS-9973) treatment, in vitro mineral resorption assay","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 — conditional genetic knockout with functional bone resorption readout and pharmacological validation","pmids":["31613396"],"is_preprint":false},{"year":2019,"finding":"SH3BP2 gain-of-function (P416R) mutation in a lupus-prone model increases TNF-α and cleaved caspase-3 in lymph nodes, reducing the B220+CD4-CD8- T cell population associated with lupus, suggesting SH3BP2 modulates lymphocyte apoptosis in autoimmune contexts","method":"Double-mutant mouse model (Sh3bp2 KI x B6.MRL-Fas), flow cytometry of lymphocyte subsets, caspase-3 immunostaining, survival and proteinuria monitoring","journal":"Cells","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis in vivo with cellular phenotype, single lab","pmids":["31052273"],"is_preprint":false},{"year":2020,"finding":"SH3BP2 gain-of-function (homozygous P416R) drives RANKL-independent osteoclastogenesis in vivo; Sh3bp2 KI/KI Rankl-/- mice develop TRAP-positive, cathepsin K-positive multinucleated osteoclasts spontaneously, with elevated serum TNF-α suggesting TNF-α drives RANKL-independent osteoclast formation downstream of SH3BP2","method":"Double-mutant mouse model (Sh3bp2 KI/KI × Rankl-/-), TRAP and cathepsin K staining, osteoclast marker gene expression in bone, serum TRAP5b and TNF-α measurement, micro-CT bone volume analysis","journal":"Bone reports","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in vivo with multiple orthogonal molecular and histological readouts","pmids":["32258251"],"is_preprint":false},{"year":2021,"finding":"SH3BP2 deficiency in a lupus-prone (Fas-mutant) model ameliorates lupus-like manifestations and suppresses dendritic cell differentiation in vitro and in vivo, without substantially affecting T cell or macrophage function, placing SH3BP2 as a regulator of dendritic cell development in autoimmunity","method":"SH3BP2-deficient lupus mouse model (Sh3bp2-/- x Fas mice), B cell-specific knockout, flow cytometry of lymphocyte/dendritic cell subsets, in vitro dendritic cell differentiation, serum anti-dsDNA antibody, renal histology","journal":"International journal of molecular sciences","confidence":"Medium","confidence_rationale":"Tier 2 — conditional and global knockout with defined cellular phenotype, single lab","pmids":["33920631"],"is_preprint":false},{"year":2018,"finding":"SH3BP2 regulates KIT and PDGFRA receptor expression in gastrointestinal stromal tumors (GISTs) through the microphthalmia-associated transcription factor (MITF); SH3BP2 silencing downregulates KIT, PDGFRA, and MITF, increases apoptosis, reduces cell migration, and suppresses tumor growth in vivo; reconstitution of both SH3BP2 and MITF restores cell viability","method":"siRNA silencing of SH3BP2 in GIST cell lines, Western blotting for KIT/PDGFRA/MITF, apoptosis assay, cell migration assay, xenograft tumor growth in vivo, MITF rescue experiment","journal":"Molecular oncology","confidence":"High","confidence_rationale":"Tier 2 — loss-of-function with in vitro and in vivo validation and epistatic rescue experiment","pmids":["29885053"],"is_preprint":false},{"year":2024,"finding":"SH3BP2 forms a signalosome complex with PLCγ2 and VAV2 in human podocytes (demonstrated by co-immunoprecipitation), and this complex is upregulated in minimal change disease and focal segmental glomerulosclerosis; Sh3bp2 KI/KI transgenic mice develop albuminuria and foot process fusion, indicating SH3BP2 signalosome drives immune activation leading to glomerular barrier dysfunction","method":"Co-immunoprecipitation of SH3BP2 with PLCγ2 and VAV2 in human podocytes, transcriptomic analysis of human glomeruli (Nephrotic Syndrome Study Network), Sh3bp2 KI/KI transgenic mouse phenotyping (albuminuria, electron microscopy, histology)","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP in relevant human cells plus in vivo genetic model, single lab","pmids":["38127456"],"is_preprint":false},{"year":2024,"finding":"SH3BP2 silencing in a spinal cord injury model inhibits microglial activation and neuroinflammation by decreasing JAK and STAT phosphorylation, placing SH3BP2 upstream of the JAK/STAT signaling pathway in microglia","method":"Lentiviral shSH3BP2 injection in SCI rats, LPS-induced BV2 microglia model, phospho-JAK/STAT Western blotting, BBB scoring, immunofluorescence, KEGG pathway analysis","journal":"Inflammation","confidence":"Medium","confidence_rationale":"Tier 2 — loss-of-function with defined molecular pathway readout in two models, single lab","pmids":["39546158"],"is_preprint":false},{"year":2024,"finding":"SH3BP2 acts as a scaffold protein at the neuromuscular junction, exhibiting polyvalent interactions with the dystrophin-glycoprotein complex (DGC) and acetylcholine receptor (AChR) pentamers to promote AChR clustering through phase separation; muscle-specific SH3BP2 deletion impairs NMJ organization, synaptic transmission, and muscle strength","method":"Muscle-specific conditional knockout mouse, neuromuscular junction imaging, AChR clustering assay, phase separation assay, protein-protein interaction studies (DGC and AChR binding), electrophysiology of synaptic transmission, grip strength measurement","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — conditional knockout with functional synaptic readout and phase separation mechanism, preprint not yet peer-reviewed","pmids":["bio_10.1101_2024.05.23.595491"],"is_preprint":true}],"current_model":"SH3BP2 is a scaffold/adaptor protein that, upon phosphorylation (e.g., by PKC), recruits 14-3-3 proteins (negatively regulating its activity) and assembles signalosomes containing PLCγ1/2, SYK, and VAV2 downstream of immune receptors (RANK, M-CSF receptor, KIT/PDGFRA) to activate the PLCγ–calcineurin–NFATc1 axis; gain-of-function cherubism mutations disrupt its tankyrase-mediated ubiquitin-proteasome degradation, causing SH3BP2 stabilization and hyperactivation of myeloid cells (macrophages and osteoclasts) with elevated TNF-α production and excessive bone resorption, while at the neuromuscular junction SH3BP2 promotes acetylcholine receptor clustering via phase separation with the dystrophin-glycoprotein complex."},"narrative":{"teleology":[{"year":2001,"claim":"Identifying SH3BP2 as the cherubism gene established that a signaling adaptor protein could drive a bone-resorptive disease, but left the molecular mechanism entirely open.","evidence":"Positional cloning and sequencing of multiple cherubism families identified seven exon 9 missense mutations","pmids":["11381256"],"confidence":"High","gaps":["Whether mutations were gain-of-function or loss-of-function was unknown","No signaling pathway downstream of SH3BP2 had been defined","Affected cell type (osteoclast vs. osteoblast vs. other) was unresolved"]},{"year":2002,"claim":"Discovery that 14-3-3 proteins bind SH3BP2 in a PKC-phosphorylation-dependent manner and suppress NFAT/AP-1 activity revealed the first negative regulatory mechanism controlling SH3BP2 signaling output.","evidence":"Yeast two-hybrid, co-IP, in vitro PKC kinase assay, phospho-site mutagenesis, and NFAT luciferase reporter in lymphocytes","pmids":["12501243"],"confidence":"High","gaps":["Relationship between 14-3-3 regulation and cherubism mutations was not tested","Whether the NFAT pathway was the effector in bone cells remained unclear"]},{"year":2006,"claim":"Demonstrating that cherubism mutations are gain-of-function alleles that hyperactivate NFAT transcription resolved the basic directionality of disease pathogenesis.","evidence":"NFAT luciferase reporter assays with multiple disease-associated SH3BP2 mutants vs. wild-type","pmids":["16786512"],"confidence":"Medium","gaps":["Mechanism by which mutations increase NFAT activity was unknown","In vivo validation of gain-of-function was lacking"]},{"year":2007,"claim":"The P416R knock-in mouse model proved that gain-of-function SH3BP2 drives TNF-α-dependent systemic inflammation and bone loss through hyperactivated myeloid cells with increased ERK1/2 and SYK phosphorylation, establishing the myeloid-intrinsic origin of cherubism.","evidence":"Knock-in mouse, fetal liver transplantation, phospho-Western for ERK1/2 and SYK, osteoclast differentiation, TNF-α measurement","pmids":["17218256"],"confidence":"High","gaps":["Direct biochemical mechanism linking mutation to SYK/ERK hyperactivation was not defined","Whether TNF-α was sufficient to drive osteoclastogenesis independently of RANKL was untested"]},{"year":2008,"claim":"Placing SH3BP2 upstream of PLCγ1/2 phosphorylation and calcineurin–NFATc1 nuclear translocation defined the core signaling cascade through which SH3BP2 promotes osteoclastogenesis.","evidence":"SH3BP2 overexpression in RAW264.7 cells with phospho-PLCγ1/2 Western blotting and NFATc1 nuclear translocation","pmids":["18440306"],"confidence":"Medium","gaps":["Whether SH3BP2 directly binds PLCγ or acts through intermediaries was unknown","Loss-of-function validation was missing"]},{"year":2010,"claim":"Convergent studies established that SH3BP2 is required for normal osteoblast function and that cherubism mutations hyperactivate the PLCγ–NFAT axis more potently than wild-type, clarifying that disease involves both osteoclast hyperactivity and osteoblast impairment.","evidence":"Knock-in mouse bone spectroscopy, osteoblast cultures, and mutant vs. wild-type PLCγ phosphorylation/NFAT reporter assays in RAW264.7 cells","pmids":["20117257","20872577"],"confidence":"High","gaps":["Molecular mechanism of SH3BP2 function in osteoblasts was uncharacterized","Whether osteoblast defect is cell-autonomous or secondary to inflammation was unclear"]},{"year":2011,"claim":"Discovery that tankyrase ADP-ribosylates SH3BP2 to target it for proteasomal degradation — and that cherubism mutations disrupt this interaction, stabilizing SH3BP2 protein — provided the biochemical explanation for the gain-of-function mechanism.","evidence":"Tankyrase–SH3BP2 interaction studies and degradation assays (described in Cell commentary citing Guettler et al. and Levaot et al.); complemented by SH3BP2 knockout and knockdown showing SH3BP2 is necessary for osteoclast differentiation and resorption","pmids":["22153068","21448930"],"confidence":"High","gaps":["Structural basis of the tankyrase–SH3BP2 interaction at atomic resolution was not reported in this entry","Whether tankyrase inhibitors phenocopy cherubism in bone was untested at this point"]},{"year":2012,"claim":"Identification of PARP1 as a transcriptional regulator of SH3BP2 expression added a layer of transcriptional control, showing that PARP1 binds the SH3BP2 promoter and is required for its expression in bone marrow macrophages.","evidence":"Promoter deletion, EMSA, ChIP, Parp1 knockout mouse BMMs, luciferase reporter","pmids":["22820184"],"confidence":"High","gaps":["Whether PARP1-dependent transcription is regulated during osteoclast differentiation was not addressed","Relationship between transcriptional and post-translational (tankyrase) regulation was unexplored"]},{"year":2014,"claim":"Demonstrating that SH3BP2 gain-of-function enables RANKL-independent, TNF-α-driven osteoclastogenesis through SYK–PLCγ2–NFATc1, and that SH3BP2 gain-of-function worsens inflammatory arthritis in a myeloid-specific manner, unified the TNF-α and RANKL signaling arms of SH3BP2 biology.","evidence":"Knock-in BMM assays with TNF-α, phospho-SYK/PLCγ2, NFATc1 translocation; collagen-induced arthritis model with micro-CT and cytokine profiling","pmids":["24916406","25144740"],"confidence":"High","gaps":["Direct physical interaction between SH3BP2 and SYK in osteoclasts was not shown by reciprocal co-IP","Therapeutic potential of targeting SH3BP2 or SYK in arthritis was not tested"]},{"year":2018,"claim":"Extending SH3BP2 function beyond immune/bone cells, SH3BP2 silencing in GISTs downregulated KIT and PDGFRA via MITF, suppressing tumor growth, revealing SH3BP2 as a regulator of receptor tyrosine kinase expression in cancer.","evidence":"siRNA knockdown in GIST cell lines, Western blotting, xenograft model, MITF rescue experiment","pmids":["29885053"],"confidence":"High","gaps":["Mechanism by which SH3BP2 regulates MITF expression or stability was not defined","Whether SH3BP2's adaptor function or a transcription-coupled mechanism is responsible was unclear"]},{"year":2019,"claim":"Conditional myeloid-specific SH3BP2 and SYK deletion established that the SH3BP2–SYK axis specifically controls osteoclast resorptive activity rather than osteoclast differentiation per se, while pharmacological tankyrase inhibition in vivo confirmed that SH3BP2 protein stabilization drives bone loss.","evidence":"LysM-Cre conditional knockout in periodontitis model, SYK inhibitor, micro-CT; tankyrase inhibitor treatment in mice with SH3BP2 protein measurement","pmids":["31613396","30813388"],"confidence":"High","gaps":["How SH3BP2–SYK selectively controls resorption without affecting differentiation was mechanistically unexplained","Whether tankyrase inhibitor bone effects are entirely SH3BP2-dependent or involve other tankyrase substrates was not resolved"]},{"year":2021,"claim":"SH3BP2 loss-of-function ameliorated lupus in Fas-mutant mice by suppressing dendritic cell differentiation, expanding the known immune cell types regulated by SH3BP2 beyond macrophages and osteoclasts.","evidence":"Sh3bp2-/- × Fas lupus mouse, flow cytometry of dendritic cells, in vitro DC differentiation, renal histology","pmids":["33920631"],"confidence":"Medium","gaps":["Signaling pathway by which SH3BP2 controls DC differentiation was not identified","Whether SH3BP2's role in DCs is cell-autonomous was not fully resolved"]},{"year":2024,"claim":"SH3BP2 was shown to form a PLCγ2–VAV2 signalosome in human podocytes driving glomerular disease, to regulate microglial JAK/STAT signaling in neuroinflammation, and to promote neuromuscular junction AChR clustering via phase separation with the dystrophin-glycoprotein complex, greatly expanding SH3BP2's functional repertoire beyond myeloid/bone biology.","evidence":"Co-IP of SH3BP2–PLCγ2–VAV2 in podocytes with KI mouse albuminuria phenotype; shSH3BP2 in SCI rats and BV2 microglia with phospho-JAK/STAT; muscle-specific conditional KO with NMJ imaging, phase separation assay, electrophysiology (preprint)","pmids":["38127456","39546158","bio_10.1101_2024.05.23.595491"],"confidence":"Medium","gaps":["Podocyte signalosome composition beyond PLCγ2 and VAV2 is undefined","JAK/STAT pathway regulation by SH3BP2 lacks biochemical mechanism","Phase separation at the NMJ is from a preprint and awaits peer review"]},{"year":null,"claim":"How SH3BP2 physically connects to SYK and PLCγ at the structural level, how cherubism mutations alter signalosome assembly beyond protein stabilization, and whether therapeutic targeting of the tankyrase–SH3BP2 axis can treat cherubism or inflammatory bone disease remain open questions.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No high-resolution structure of SH3BP2 in complex with SYK, PLCγ, or tankyrase has been reported","Whether SH3BP2 phase separation is a general mechanism across cell types is untested","Therapeutic validation of SH3BP2 pathway inhibition in cherubism patients is absent"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[1,4,18,20]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[1,4]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[20,18]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[3,10,11,13,16]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[1,4,5,10,19]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[6,7,20]}],"complexes":["SH3BP2–PLCγ2–VAV2 signalosome"],"partners":["SYK","PLCG1","PLCG2","VAV2","TNKS","YWHAB","MITF"],"other_free_text":[]},"mechanistic_narrative":"SH3BP2 is a multi-domain scaffold/adaptor protein that orchestrates signaling downstream of immune and cytokine receptors to control myeloid cell differentiation, osteoclast function, and inflammatory responses. It assembles signalosomes containing PLCγ1/2, SYK, and VAV2 to activate the PLCγ–calcineurin–NFATc1 transcriptional axis during RANKL- and TNF-α-induced osteoclastogenesis, and its activity is negatively regulated by PKC-dependent phosphorylation that recruits 14-3-3 proteins and by tankyrase-mediated ADP-ribosylation targeting it for proteasomal degradation [PMID:12501243, PMID:18440306, PMID:22153068]. Gain-of-function missense mutations in exon 9 cause cherubism, an autosomal dominant disorder of excessive jaw bone resorption: these mutations disrupt tankyrase-dependent degradation, stabilize SH3BP2, and hyperactivate myeloid cells to produce elevated TNF-α and drive RANKL-independent osteoclastogenesis [PMID:11381256, PMID:17218256, PMID:32258251]. Loss-of-function studies demonstrate that SH3BP2 is also required for normal osteoblast differentiation, dendritic cell development, and osteoclast resorptive activity via the SH3BP2–SYK axis, and it additionally functions at the neuromuscular junction where it promotes acetylcholine receptor clustering through phase-separation-mediated interactions with the dystrophin-glycoprotein complex [PMID:20117257, PMID:31613396, PMID:33920631]."},"prefetch_data":{"uniprot":{"accession":"P78314","full_name":"SH3 domain-binding protein 2","aliases":[],"length_aa":561,"mass_kda":62.2,"function":"Binds differentially to the SH3 domains of certain proteins of signal transduction pathways. Binds to phosphatidylinositols; linking the hemopoietic tyrosine kinase fes to the cytoplasmic membrane in a phosphorylation dependent mechanism","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/P78314/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SH3BP2","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SH3BP2","total_profiled":1310},"omim":[{"mim_id":"621133","title":"OPIOID GROWTH FACTOR RECEPTOR-LIKE PROTEIN 1; OGFRL1","url":"https://www.omim.org/entry/621133"},{"mim_id":"602104","title":"SH3 DOMAIN-BINDING PROTEIN 2; SH3BP2","url":"https://www.omim.org/entry/602104"},{"mim_id":"118400","title":"CHERUBISM","url":"https://www.omim.org/entry/118400"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Golgi apparatus","reliability":"Approved"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/SH3BP2"},"hgnc":{"alias_symbol":["RES4-23","CRBM"],"prev_symbol":[]},"alphafold":{"accession":"P78314","domains":[{"cath_id":"2.30.29.30","chopping":"16-131_152-156","consensus_level":"high","plddt":90.5635,"start":16,"end":156},{"cath_id":"3.30.505.10","chopping":"454-553","consensus_level":"high","plddt":91.939,"start":454,"end":553}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P78314","model_url":"https://alphafold.ebi.ac.uk/files/AF-P78314-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P78314-F1-predicted_aligned_error_v6.png","plddt_mean":65.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SH3BP2","jax_strain_url":"https://www.jax.org/strain/search?query=SH3BP2"},"sequence":{"accession":"P78314","fasta_url":"https://rest.uniprot.org/uniprotkb/P78314.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P78314/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P78314"}},"corpus_meta":[{"pmid":"11381256","id":"PMC_11381256","title":"Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism.","date":"2001","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11381256","citation_count":276,"is_preprint":false},{"pmid":"17218256","id":"PMC_17218256","title":"Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 \"cherubism\" mice.","date":"2007","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/17218256","citation_count":149,"is_preprint":false},{"pmid":"22640988","id":"PMC_22640988","title":"The role of SH3BP2 in the pathophysiology of cherubism.","date":"2012","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/22640988","citation_count":73,"is_preprint":false},{"pmid":"24916406","id":"PMC_24916406","title":"SH3BP2 cherubism mutation potentiates TNF-α-induced osteoclastogenesis via NFATc1 and TNF-α-mediated inflammatory bone loss.","date":"2014","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/24916406","citation_count":53,"is_preprint":false},{"pmid":"12501243","id":"PMC_12501243","title":"The chaperone protein 14-3-3 interacts with 3BP2/SH3BP2 and regulates its adapter function.","date":"2002","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12501243","citation_count":46,"is_preprint":false},{"pmid":"12900899","id":"PMC_12900899","title":"Novel mutation in the gene encoding c-Abl-binding protein SH3BP2 causes cherubism.","date":"2003","source":"American journal of medical genetics. Part A","url":"https://pubmed.ncbi.nlm.nih.gov/12900899","citation_count":40,"is_preprint":false},{"pmid":"14577811","id":"PMC_14577811","title":"A missense mutation in the SH3BP2 gene on chromosome 4p16.3 found in a case of nonfamilial cherubism.","date":"2003","source":"The Cleft palate-craniofacial journal : official publication of the American Cleft Palate-Craniofacial Association","url":"https://pubmed.ncbi.nlm.nih.gov/14577811","citation_count":39,"is_preprint":false},{"pmid":"16786512","id":"PMC_16786512","title":"Identification of a novel mutation of SH3BP2 in cherubism and demonstration that SH3BP2 mutations lead to increased NFAT activation.","date":"2006","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/16786512","citation_count":35,"is_preprint":false},{"pmid":"9299232","id":"PMC_9299232","title":"Identification and characterization of the human homologue of SH3BP2, an SH3 binding domain protein within a common region of deletion at 4p16.3 involved in bladder cancer.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9299232","citation_count":34,"is_preprint":false},{"pmid":"18440306","id":"PMC_18440306","title":"SH3BP2 is an activator of NFAT activity and osteoclastogenesis.","date":"2008","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/18440306","citation_count":30,"is_preprint":false},{"pmid":"17544554","id":"PMC_17544554","title":"Mutations in SH3BP2, the cherubism gene, were not detected in central or peripheral giant cell tumours of the jaw.","date":"2007","source":"The British journal of oral & maxillofacial surgery","url":"https://pubmed.ncbi.nlm.nih.gov/17544554","citation_count":30,"is_preprint":false},{"pmid":"30813388","id":"PMC_30813388","title":"Tankyrase (PARP5) Inhibition Induces Bone Loss through Accumulation of Its Substrate SH3BP2.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/30813388","citation_count":29,"is_preprint":false},{"pmid":"19017279","id":"PMC_19017279","title":"Novel mutations in the SH3BP2 gene associated with sporadic central giant cell lesions and cherubism.","date":"2008","source":"Oral diseases","url":"https://pubmed.ncbi.nlm.nih.gov/19017279","citation_count":29,"is_preprint":false},{"pmid":"24978678","id":"PMC_24978678","title":"Etanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss.","date":"2014","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/24978678","citation_count":27,"is_preprint":false},{"pmid":"17147794","id":"PMC_17147794","title":"A novel mutation in the SH3BP2 gene causes cherubism: case report.","date":"2006","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17147794","citation_count":26,"is_preprint":false},{"pmid":"16713042","id":"PMC_16713042","title":"DNA analysis of the SH3BP2 gene in patients with aggressive central giant cell granuloma.","date":"2006","source":"The British journal of oral & maxillofacial surgery","url":"https://pubmed.ncbi.nlm.nih.gov/16713042","citation_count":22,"is_preprint":false},{"pmid":"25144740","id":"PMC_25144740","title":"SH3BP2 gain-of-function mutation exacerbates inflammation and bone loss in a murine collagen-induced arthritis model.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25144740","citation_count":21,"is_preprint":false},{"pmid":"17368082","id":"PMC_17368082","title":"A novel mutation of the SH3BP2 gene in an aggressive case of cherubism.","date":"2007","source":"Oral oncology","url":"https://pubmed.ncbi.nlm.nih.gov/17368082","citation_count":17,"is_preprint":false},{"pmid":"31613396","id":"PMC_31613396","title":"Alveolar Bone Protection by Targeting the SH3BP2-SYK Axis in Osteoclasts.","date":"2019","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/31613396","citation_count":16,"is_preprint":false},{"pmid":"20117257","id":"PMC_20117257","title":"Pro416Arg cherubism mutation in Sh3bp2 knock-in mice affects osteoblasts and alters bone mineral and matrix properties.","date":"2010","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/20117257","citation_count":15,"is_preprint":false},{"pmid":"17545756","id":"PMC_17545756","title":"SH3BP2 is rarely mutated in exon 9 in giant cell lesions outside cherubism.","date":"2007","source":"Clinical orthopaedics and related research","url":"https://pubmed.ncbi.nlm.nih.gov/17545756","citation_count":14,"is_preprint":false},{"pmid":"20691350","id":"PMC_20691350","title":"Cherubism gene Sh3bp2 is important for optimal bone formation, osteoblast differentiation, and function.","date":"2010","source":"American journal of orthodontics and dentofacial orthopedics : official publication of the American Association of Orthodontists, its constituent societies, and the American Board of Orthodontics","url":"https://pubmed.ncbi.nlm.nih.gov/20691350","citation_count":13,"is_preprint":false},{"pmid":"31052273","id":"PMC_31052273","title":"Sh3bp2 Gain-Of-Function Mutation Ameliorates Lupus Phenotypes in B6.MRL-Fas Mice.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31052273","citation_count":13,"is_preprint":false},{"pmid":"29885053","id":"PMC_29885053","title":"Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth.","date":"2018","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29885053","citation_count":12,"is_preprint":false},{"pmid":"21680150","id":"PMC_21680150","title":"SH3BP2-encoding exons involved in cherubism are not associated with central giant cell granuloma.","date":"2011","source":"International journal of oral and maxillofacial surgery","url":"https://pubmed.ncbi.nlm.nih.gov/21680150","citation_count":11,"is_preprint":false},{"pmid":"21045962","id":"PMC_21045962","title":"Identical Mutation in SH3BP2 Gene Causes Clinical Phenotypes with Different Severity in Mother and Daughter - Case Report.","date":"2010","source":"Molecular syndromology","url":"https://pubmed.ncbi.nlm.nih.gov/21045962","citation_count":11,"is_preprint":false},{"pmid":"18596838","id":"PMC_18596838","title":"Investigation of the SH3BP2 gene mutation in cherubism.","date":"2008","source":"Acta medica Okayama","url":"https://pubmed.ncbi.nlm.nih.gov/18596838","citation_count":10,"is_preprint":false},{"pmid":"33920631","id":"PMC_33920631","title":"SH3BP2 Deficiency Ameliorates Murine Systemic Lupus Erythematosus.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33920631","citation_count":10,"is_preprint":false},{"pmid":"32258251","id":"PMC_32258251","title":"RANKL-independent osteoclastogenesis in the SH3BP2 cherubism mice.","date":"2020","source":"Bone reports","url":"https://pubmed.ncbi.nlm.nih.gov/32258251","citation_count":8,"is_preprint":false},{"pmid":"20872577","id":"PMC_20872577","title":"SH3BP2 mutations potentiate osteoclastogenesis via PLCγ.","date":"2010","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/20872577","citation_count":8,"is_preprint":false},{"pmid":"33941395","id":"PMC_33941395","title":"SH3BP2-related fibro-osseous disorders of the maxilla and mandible: A systematic review.","date":"2021","source":"International journal of oral and maxillofacial surgery","url":"https://pubmed.ncbi.nlm.nih.gov/33941395","citation_count":6,"is_preprint":false},{"pmid":"23083484","id":"PMC_23083484","title":"A novel c.1255G>T (p.D419Y) mutation in SH3BP2 gene causes cherubism in a Turkish family.","date":"2012","source":"Oral surgery, oral medicine, oral pathology and oral radiology","url":"https://pubmed.ncbi.nlm.nih.gov/23083484","citation_count":6,"is_preprint":false},{"pmid":"22153068","id":"PMC_22153068","title":"Tankyrase loses its grip on SH3BP2 in cherubism.","date":"2011","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22153068","citation_count":6,"is_preprint":false},{"pmid":"38127456","id":"PMC_38127456","title":"Scaffold protein SH3BP2 signalosome is pivotal for immune activation in nephrotic syndrome.","date":"2024","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/38127456","citation_count":5,"is_preprint":false},{"pmid":"35079675","id":"PMC_35079675","title":"Tlr2/4-Mediated Hyperinflammation Promotes Cherubism-Like Jawbone Expansion in Sh3bp2 (P416R) Knockin Mice.","date":"2021","source":"JBMR plus","url":"https://pubmed.ncbi.nlm.nih.gov/35079675","citation_count":5,"is_preprint":false},{"pmid":"36551682","id":"PMC_36551682","title":"SH3BP2 Silencing Increases miRNAs Targeting ETV1 and Microphthalmia-Associated Transcription Factor, Decreasing the Proliferation of Gastrointestinal Stromal Tumors.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36551682","citation_count":5,"is_preprint":false},{"pmid":"22795151","id":"PMC_22795151","title":"Mutations of the SH3BP2 gene in 2 families of cherubism.","date":"2012","source":"Pediatric dentistry","url":"https://pubmed.ncbi.nlm.nih.gov/22795151","citation_count":5,"is_preprint":false},{"pmid":"25445458","id":"PMC_25445458","title":"Bone marrow transplantation improves autoinflammation and inflammatory bone loss in SH3BP2 knock-in cherubism mice.","date":"2014","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/25445458","citation_count":5,"is_preprint":false},{"pmid":"24608212","id":"PMC_24608212","title":"A c.1244G>A (p.Arg415Gln) mutation in SH3BP2 gene causes cherubism in a Turkish family: report of a family with review of the literature.","date":"2014","source":"Medicina oral, patologia oral y cirugia bucal","url":"https://pubmed.ncbi.nlm.nih.gov/24608212","citation_count":4,"is_preprint":false},{"pmid":"24712477","id":"PMC_24712477","title":"Novel nucleotide mutation leading to a recurrent amino acid alteration in SH3BP2 in a patient with cherubism.","date":"2013","source":"Congenital anomalies","url":"https://pubmed.ncbi.nlm.nih.gov/24712477","citation_count":4,"is_preprint":false},{"pmid":"35481344","id":"PMC_35481344","title":"Overexpression of DEL-1 Downregulates SH3BP2 Expression and Inhibits Porphyromonas gingivalis-induced Gingival Inflammation In Vivo and In Vitro.","date":"2022","source":"Oral health & preventive dentistry","url":"https://pubmed.ncbi.nlm.nih.gov/35481344","citation_count":4,"is_preprint":false},{"pmid":"21448930","id":"PMC_21448930","title":"Decreased SH3BP2 inhibits osteoclast differentiation and function.","date":"2011","source":"Journal of orthopaedic research : official publication of the Orthopaedic Research Society","url":"https://pubmed.ncbi.nlm.nih.gov/21448930","citation_count":3,"is_preprint":false},{"pmid":"22820184","id":"PMC_22820184","title":"Cloning and characterization of the human SH3BP2 promoter.","date":"2012","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/22820184","citation_count":3,"is_preprint":false},{"pmid":"39546158","id":"PMC_39546158","title":"Silencing of SH3BP2 Inhibits Microglia Activation Via the JAK/STAT Signaling in Spinal Cord Injury Models.","date":"2024","source":"Inflammation","url":"https://pubmed.ncbi.nlm.nih.gov/39546158","citation_count":2,"is_preprint":false},{"pmid":"16836910","id":"PMC_16836910","title":"[Mutation detection in SH3BP2 gene in a cherubism family].","date":"2006","source":"Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology","url":"https://pubmed.ncbi.nlm.nih.gov/16836910","citation_count":2,"is_preprint":false},{"pmid":"39991193","id":"PMC_39991193","title":"Emerging Role of SH3BP2 as Regulator of Immune and Nonimmune Cells in Nephrotic Syndrome.","date":"2024","source":"Glomerular diseases","url":"https://pubmed.ncbi.nlm.nih.gov/39991193","citation_count":1,"is_preprint":false},{"pmid":"18953613","id":"PMC_18953613","title":"SH3BP2 is a critical regulator of macrophage and osteoclast response to M-CSF and RANKL stimulation.","date":"2008","source":"HSS journal : the musculoskeletal journal of Hospital for Special Surgery","url":"https://pubmed.ncbi.nlm.nih.gov/18953613","citation_count":1,"is_preprint":false},{"pmid":"41635508","id":"PMC_41635508","title":"Paeoniflorin Ameliorates Metabolic Dysfunction-Associated Steatotic Liver Disease by SYK/SH3BP2 Signaling Pathway.","date":"2026","source":"Research (Washington, D.C.)","url":"https://pubmed.ncbi.nlm.nih.gov/41635508","citation_count":0,"is_preprint":false},{"pmid":"41019663","id":"PMC_41019663","title":"Comparative analysis of osteoclast function in symptomatic and asymptomatic individuals with cherubism-causing SH3BP2 mutation.","date":"2025","source":"JBMR plus","url":"https://pubmed.ncbi.nlm.nih.gov/41019663","citation_count":0,"is_preprint":false},{"pmid":"19576004","id":"PMC_19576004","title":"[Gene mutation and expression of SH-3BP-2 in cherubism].","date":"2009","source":"Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology","url":"https://pubmed.ncbi.nlm.nih.gov/19576004","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.05.23.595491","title":"SH3BP2 regulates the organization of the neuromuscular synapses through protein-driven phase separation","date":"2024-05-23","source":"bioRxiv","url":"https://doi.org/10.1101/2024.05.23.595491","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":24242,"output_tokens":5412,"usd":0.076953},"stage2":{"model":"claude-opus-4-6","input_tokens":9035,"output_tokens":3873,"usd":0.213},"total_usd":0.289953,"stage1_batch_id":"msgbatch_011rkcQdVV1RaFq9XhcG6df6","stage2_batch_id":"msgbatch_01RzgrJafdF4EWHhj5mNi6dh","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"Missense mutations in SH3BP2 (an SH3-binding adaptor protein with SH2, SH3-binding, and pleckstrin homology domains) cause cherubism, identifying SH3BP2 as the disease gene on chromosome 4p16.3\",\n      \"method\": \"Direct DNA sequencing of affected families; identification of seven mutations in exon 9\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — original disease-gene identification replicated across multiple families and labs\",\n      \"pmids\": [\"11381256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"14-3-3 chaperone proteins physically interact with SH3BP2 in a phosphorylation-dependent manner; PKC-mediated phosphorylation of SH3BP2 at Ser225 and Ser277 is required for 14-3-3 binding, and this interaction negatively regulates SH3BP2-dependent NFAT/AP-1 transcriptional activity in lymphocytes\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, alkaline phosphatase dephosphorylation, in vitro PKC kinase assay, deletion/point mutagenesis, NFAT luciferase reporter assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods including in vitro kinase assay, mutagenesis, and functional reporter assay in single study\",\n      \"pmids\": [\"12501243\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Cherubism-associated exon 9 missense mutations in SH3BP2 (R415Q, D419N, D420E, P418R) are gain-of-function mutations that increase NFAT transcriptional activity, indicating that cherubism results from gain-of-function SH3BP2 mutations acting through NFAT activation\",\n      \"method\": \"Transient transfection of mutant SH3BP2 constructs in cells with NFAT luciferase reporter assay\",\n      \"journal\": \"Human mutation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional gain-of-function assay with multiple mutants, single lab\",\n      \"pmids\": [\"16786512\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SH3BP2 cherubism knock-in mice (P416R) exhibit TNF-α-dependent systemic inflammation and bone loss; mutant myeloid cells show increased ERK1/2 and SYK phosphorylation/activation upon M-CSF and RANKL stimulation, forming macrophages with elevated TNF-α and unusually large osteoclasts; the phenotype is lymphocyte-independent and transferable via fetal liver cells, establishing SH3BP2 as a gain-of-function regulator of myeloid cell responses\",\n      \"method\": \"Knock-in mouse model, bone marrow/fetal liver transplantation, phospho-Western blotting (ERK1/2, SYK), osteoclast differentiation assays, TNF-α measurement, M-CSF/RANKL stimulation experiments\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — rigorous in vivo genetic model with multiple orthogonal mechanistic readouts, highly cited foundational paper\",\n      \"pmids\": [\"17218256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"SH3BP2 overexpression in RAW 264.7 pre-osteoclast cells increases nuclear NFATc1 translocation, TRAP expression, and potentiates sRANKL-stimulated phosphorylation of PLCγ1 and PLCγ2, placing SH3BP2 upstream of PLCγ-calcineurin-NFATc1 in RANKL-induced osteoclastogenesis\",\n      \"method\": \"Overexpression of SH3BP2 in RAW264.7 cells, Western blotting for phospho-PLCγ1/2 and nuclear NFATc1, TRAP staining as osteoclast differentiation marker\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined mechanistic pathway in cell-based assays, single lab\",\n      \"pmids\": [\"18440306\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Mutant SH3BP2 (cherubism mutations) stimulates RANKL-induced PLCγ1/2 phosphorylation more potently than wild-type SH3BP2, resulting in greater NFAT activity and TRAP expression; gain-of-function mechanism operates through the PLCγ-calcineurin-NFAT axis\",\n      \"method\": \"Transfection of wild-type vs. mutant SH3BP2 in RAW264.7 cells, NFAT-luciferase reporter assay, phospho-PLCγ Western blotting, TRAP assay\",\n      \"journal\": \"Journal of orthopaedic research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway defined with multiple readouts, single lab replicating earlier finding\",\n      \"pmids\": [\"20872577\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"SH3BP2 is required for normal osteoblast differentiation and function; the P416R cherubism knock-in mutation reduces mature osteoblast numbers, decreases mineral content and crystallinity in bone, and impairs osteoblast-specific gene expression and mineralization in calvarial cultures\",\n      \"method\": \"Knock-in mouse model, FTIRI spectroscopy of bone, GFP-reporter transgenic cross for osteoblast counting, hematopoietic cell-depleted calvarial osteoblast cultures, gene expression analysis, co-culture osteoclastogenesis assay\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (spectroscopy, cell culture, transgenic reporter, co-culture) in single study\",\n      \"pmids\": [\"20117257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"shRNA knockdown of SH3BP2 decreases PLCγ2 phosphorylation and NFATc1 expression, reduces osteoclast number, size, and TRAP staining, and dramatically blocks bone resorptive activity; Sh3bp2-/- BMMs form smaller osteoclasts with reduced TRAP staining, demonstrating SH3BP2 is necessary for osteoclast differentiation and function\",\n      \"method\": \"shRNA knockdown in RAW264.7 cells and BMMs, phospho-PLCγ2 Western blotting, NFATc1 expression analysis, TRAP staining, bone resorption pit assay, Sh3bp2-/- mouse BMM cultures\",\n      \"journal\": \"Journal of orthopaedic research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined molecular phenotype replicated in both knockdown and knockout cells with multiple readouts\",\n      \"pmids\": [\"21448930\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Tankyrase (PARP5) interacts with SH3BP2 and marks it for degradation; cherubism mutations in SH3BP2 disrupt the tankyrase-SH3BP2 interaction, leading to SH3BP2 stabilization (gain-of-function)\",\n      \"method\": \"Referenced as described in Guettler et al. and Levaot et al. in the same Cell issue (commentary paper)\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — described via commentary citing two primary papers in same issue; mechanistic claim well established but this entry is a review/preview\",\n      \"pmids\": [\"22153068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PARP1 binds to a specific element (-44 to -21) in the SH3BP2 promoter and is required for SH3BP2 transcriptional expression; mutagenesis of the PARP1 binding site abolishes SH3BP2 promoter activity, and Parp1 knockout reduces SH3BP2 expression in BMMs\",\n      \"method\": \"Promoter deletion analysis, streptavidin-biotin DNA pulldown, EMSA, ChIP assay, Parp1 knockout mouse BMMs, luciferase reporter\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro EMSA and in vivo ChIP with mutagenesis and genetic knockout validation\",\n      \"pmids\": [\"22820184\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The P416R SH3BP2 cherubism mutation enables TNF-α-induced osteoclastogenesis independently of RANKL, through a mechanism involving SYK and PLCγ2 phosphorylation leading to increased NFATc1 nuclear translocation; SH3BP2 knockdown in RAW264.7 cells reduces TNF-α-induced osteoclastogenesis\",\n      \"method\": \"BMM differentiation assays from heterozygous knock-in mice with TNF-α, phospho-SYK/PLCγ2 Western blotting, NFATc1 nuclear translocation assay, calvarial TNF-α injection model, human TNF-α transgenic mouse model, shRNA knockdown\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple in vitro and in vivo models with defined molecular mechanism across multiple readouts\",\n      \"pmids\": [\"24916406\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"SH3BP2 gain-of-function (P416R) augments inflammation and bone loss in collagen-induced arthritis through increased macrophage TNF-α production and enhanced RANKL-induced osteoclastogenesis with increased NFATc1 nuclear localization; lymphocyte responses are not significantly affected\",\n      \"method\": \"CIA model in Sh3bp2 KI/+ mice, histological joint analysis, micro-CT bone loss quantification, cytokine gene expression, BMM TNF-α production, NFATc1 immunostaining, lymph node proliferation assay, serum antibody measurement\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistatic in vivo model with multiple orthogonal mechanistic readouts confirming myeloid-cell-specific mechanism\",\n      \"pmids\": [\"25144740\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Tankyrase (PARP5) catalyzes ADP-ribosylation of SH3BP2 targeting it for proteasomal degradation; pharmacological tankyrase inhibition in mice causes SH3BP2 accumulation leading to increased osteoclast formation and bone loss\",\n      \"method\": \"Tankyrase inhibitor treatment in mice, bone phenotype analysis, SH3BP2 protein level measurement (reviewed mechanistic pathway)\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo pharmacological evidence linking tankyrase activity to SH3BP2 stability and bone loss, review summarizing primary data\",\n      \"pmids\": [\"30813388\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SH3BP2-SYK signaling axis in osteoclasts controls alveolar bone resorption function (rather than osteoclast differentiation) in periodontitis; conditional knockout of SH3BP2 and SYK in myeloid cells (LysM-Cre) reduces alveolar bone loss without affecting inflammatory cytokine expression or osteoclast number\",\n      \"method\": \"Sh3bp2-/- mouse ligature-induced periodontitis model, micro-CT bone loss analysis, conditional myeloid-specific knockout (LysM-Cre), SYK inhibitor (GS-9973) treatment, in vitro mineral resorption assay\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional genetic knockout with functional bone resorption readout and pharmacological validation\",\n      \"pmids\": [\"31613396\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"SH3BP2 gain-of-function (P416R) mutation in a lupus-prone model increases TNF-α and cleaved caspase-3 in lymph nodes, reducing the B220+CD4-CD8- T cell population associated with lupus, suggesting SH3BP2 modulates lymphocyte apoptosis in autoimmune contexts\",\n      \"method\": \"Double-mutant mouse model (Sh3bp2 KI x B6.MRL-Fas), flow cytometry of lymphocyte subsets, caspase-3 immunostaining, survival and proteinuria monitoring\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo with cellular phenotype, single lab\",\n      \"pmids\": [\"31052273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SH3BP2 gain-of-function (homozygous P416R) drives RANKL-independent osteoclastogenesis in vivo; Sh3bp2 KI/KI Rankl-/- mice develop TRAP-positive, cathepsin K-positive multinucleated osteoclasts spontaneously, with elevated serum TNF-α suggesting TNF-α drives RANKL-independent osteoclast formation downstream of SH3BP2\",\n      \"method\": \"Double-mutant mouse model (Sh3bp2 KI/KI × Rankl-/-), TRAP and cathepsin K staining, osteoclast marker gene expression in bone, serum TRAP5b and TNF-α measurement, micro-CT bone volume analysis\",\n      \"journal\": \"Bone reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo with multiple orthogonal molecular and histological readouts\",\n      \"pmids\": [\"32258251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SH3BP2 deficiency in a lupus-prone (Fas-mutant) model ameliorates lupus-like manifestations and suppresses dendritic cell differentiation in vitro and in vivo, without substantially affecting T cell or macrophage function, placing SH3BP2 as a regulator of dendritic cell development in autoimmunity\",\n      \"method\": \"SH3BP2-deficient lupus mouse model (Sh3bp2-/- x Fas mice), B cell-specific knockout, flow cytometry of lymphocyte/dendritic cell subsets, in vitro dendritic cell differentiation, serum anti-dsDNA antibody, renal histology\",\n      \"journal\": \"International journal of molecular sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional and global knockout with defined cellular phenotype, single lab\",\n      \"pmids\": [\"33920631\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SH3BP2 regulates KIT and PDGFRA receptor expression in gastrointestinal stromal tumors (GISTs) through the microphthalmia-associated transcription factor (MITF); SH3BP2 silencing downregulates KIT, PDGFRA, and MITF, increases apoptosis, reduces cell migration, and suppresses tumor growth in vivo; reconstitution of both SH3BP2 and MITF restores cell viability\",\n      \"method\": \"siRNA silencing of SH3BP2 in GIST cell lines, Western blotting for KIT/PDGFRA/MITF, apoptosis assay, cell migration assay, xenograft tumor growth in vivo, MITF rescue experiment\",\n      \"journal\": \"Molecular oncology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with in vitro and in vivo validation and epistatic rescue experiment\",\n      \"pmids\": [\"29885053\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SH3BP2 forms a signalosome complex with PLCγ2 and VAV2 in human podocytes (demonstrated by co-immunoprecipitation), and this complex is upregulated in minimal change disease and focal segmental glomerulosclerosis; Sh3bp2 KI/KI transgenic mice develop albuminuria and foot process fusion, indicating SH3BP2 signalosome drives immune activation leading to glomerular barrier dysfunction\",\n      \"method\": \"Co-immunoprecipitation of SH3BP2 with PLCγ2 and VAV2 in human podocytes, transcriptomic analysis of human glomeruli (Nephrotic Syndrome Study Network), Sh3bp2 KI/KI transgenic mouse phenotyping (albuminuria, electron microscopy, histology)\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP in relevant human cells plus in vivo genetic model, single lab\",\n      \"pmids\": [\"38127456\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SH3BP2 silencing in a spinal cord injury model inhibits microglial activation and neuroinflammation by decreasing JAK and STAT phosphorylation, placing SH3BP2 upstream of the JAK/STAT signaling pathway in microglia\",\n      \"method\": \"Lentiviral shSH3BP2 injection in SCI rats, LPS-induced BV2 microglia model, phospho-JAK/STAT Western blotting, BBB scoring, immunofluorescence, KEGG pathway analysis\",\n      \"journal\": \"Inflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — loss-of-function with defined molecular pathway readout in two models, single lab\",\n      \"pmids\": [\"39546158\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"SH3BP2 acts as a scaffold protein at the neuromuscular junction, exhibiting polyvalent interactions with the dystrophin-glycoprotein complex (DGC) and acetylcholine receptor (AChR) pentamers to promote AChR clustering through phase separation; muscle-specific SH3BP2 deletion impairs NMJ organization, synaptic transmission, and muscle strength\",\n      \"method\": \"Muscle-specific conditional knockout mouse, neuromuscular junction imaging, AChR clustering assay, phase separation assay, protein-protein interaction studies (DGC and AChR binding), electrophysiology of synaptic transmission, grip strength measurement\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — conditional knockout with functional synaptic readout and phase separation mechanism, preprint not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2024.05.23.595491\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"SH3BP2 is a scaffold/adaptor protein that, upon phosphorylation (e.g., by PKC), recruits 14-3-3 proteins (negatively regulating its activity) and assembles signalosomes containing PLCγ1/2, SYK, and VAV2 downstream of immune receptors (RANK, M-CSF receptor, KIT/PDGFRA) to activate the PLCγ–calcineurin–NFATc1 axis; gain-of-function cherubism mutations disrupt its tankyrase-mediated ubiquitin-proteasome degradation, causing SH3BP2 stabilization and hyperactivation of myeloid cells (macrophages and osteoclasts) with elevated TNF-α production and excessive bone resorption, while at the neuromuscular junction SH3BP2 promotes acetylcholine receptor clustering via phase separation with the dystrophin-glycoprotein complex.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"SH3BP2 is a multi-domain scaffold/adaptor protein that orchestrates signaling downstream of immune and cytokine receptors to control myeloid cell differentiation, osteoclast function, and inflammatory responses. It assembles signalosomes containing PLCγ1/2, SYK, and VAV2 to activate the PLCγ–calcineurin–NFATc1 transcriptional axis during RANKL- and TNF-α-induced osteoclastogenesis, and its activity is negatively regulated by PKC-dependent phosphorylation that recruits 14-3-3 proteins and by tankyrase-mediated ADP-ribosylation targeting it for proteasomal degradation [PMID:12501243, PMID:18440306, PMID:22153068]. Gain-of-function missense mutations in exon 9 cause cherubism, an autosomal dominant disorder of excessive jaw bone resorption: these mutations disrupt tankyrase-dependent degradation, stabilize SH3BP2, and hyperactivate myeloid cells to produce elevated TNF-α and drive RANKL-independent osteoclastogenesis [PMID:11381256, PMID:17218256, PMID:32258251]. Loss-of-function studies demonstrate that SH3BP2 is also required for normal osteoblast differentiation, dendritic cell development, and osteoclast resorptive activity via the SH3BP2–SYK axis, and it additionally functions at the neuromuscular junction where it promotes acetylcholine receptor clustering through phase-separation-mediated interactions with the dystrophin-glycoprotein complex [PMID:20117257, PMID:31613396, PMID:33920631].\",\n  \"teleology\": [\n    {\n      \"year\": 2001,\n      \"claim\": \"Identifying SH3BP2 as the cherubism gene established that a signaling adaptor protein could drive a bone-resorptive disease, but left the molecular mechanism entirely open.\",\n      \"evidence\": \"Positional cloning and sequencing of multiple cherubism families identified seven exon 9 missense mutations\",\n      \"pmids\": [\"11381256\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether mutations were gain-of-function or loss-of-function was unknown\",\n        \"No signaling pathway downstream of SH3BP2 had been defined\",\n        \"Affected cell type (osteoclast vs. osteoblast vs. other) was unresolved\"\n      ]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Discovery that 14-3-3 proteins bind SH3BP2 in a PKC-phosphorylation-dependent manner and suppress NFAT/AP-1 activity revealed the first negative regulatory mechanism controlling SH3BP2 signaling output.\",\n      \"evidence\": \"Yeast two-hybrid, co-IP, in vitro PKC kinase assay, phospho-site mutagenesis, and NFAT luciferase reporter in lymphocytes\",\n      \"pmids\": [\"12501243\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Relationship between 14-3-3 regulation and cherubism mutations was not tested\",\n        \"Whether the NFAT pathway was the effector in bone cells remained unclear\"\n      ]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Demonstrating that cherubism mutations are gain-of-function alleles that hyperactivate NFAT transcription resolved the basic directionality of disease pathogenesis.\",\n      \"evidence\": \"NFAT luciferase reporter assays with multiple disease-associated SH3BP2 mutants vs. wild-type\",\n      \"pmids\": [\"16786512\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Mechanism by which mutations increase NFAT activity was unknown\",\n        \"In vivo validation of gain-of-function was lacking\"\n      ]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"The P416R knock-in mouse model proved that gain-of-function SH3BP2 drives TNF-α-dependent systemic inflammation and bone loss through hyperactivated myeloid cells with increased ERK1/2 and SYK phosphorylation, establishing the myeloid-intrinsic origin of cherubism.\",\n      \"evidence\": \"Knock-in mouse, fetal liver transplantation, phospho-Western for ERK1/2 and SYK, osteoclast differentiation, TNF-α measurement\",\n      \"pmids\": [\"17218256\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Direct biochemical mechanism linking mutation to SYK/ERK hyperactivation was not defined\",\n        \"Whether TNF-α was sufficient to drive osteoclastogenesis independently of RANKL was untested\"\n      ]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Placing SH3BP2 upstream of PLCγ1/2 phosphorylation and calcineurin–NFATc1 nuclear translocation defined the core signaling cascade through which SH3BP2 promotes osteoclastogenesis.\",\n      \"evidence\": \"SH3BP2 overexpression in RAW264.7 cells with phospho-PLCγ1/2 Western blotting and NFATc1 nuclear translocation\",\n      \"pmids\": [\"18440306\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether SH3BP2 directly binds PLCγ or acts through intermediaries was unknown\",\n        \"Loss-of-function validation was missing\"\n      ]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Convergent studies established that SH3BP2 is required for normal osteoblast function and that cherubism mutations hyperactivate the PLCγ–NFAT axis more potently than wild-type, clarifying that disease involves both osteoclast hyperactivity and osteoblast impairment.\",\n      \"evidence\": \"Knock-in mouse bone spectroscopy, osteoblast cultures, and mutant vs. wild-type PLCγ phosphorylation/NFAT reporter assays in RAW264.7 cells\",\n      \"pmids\": [\"20117257\", \"20872577\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Molecular mechanism of SH3BP2 function in osteoblasts was uncharacterized\",\n        \"Whether osteoblast defect is cell-autonomous or secondary to inflammation was unclear\"\n      ]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Discovery that tankyrase ADP-ribosylates SH3BP2 to target it for proteasomal degradation — and that cherubism mutations disrupt this interaction, stabilizing SH3BP2 protein — provided the biochemical explanation for the gain-of-function mechanism.\",\n      \"evidence\": \"Tankyrase–SH3BP2 interaction studies and degradation assays (described in Cell commentary citing Guettler et al. and Levaot et al.); complemented by SH3BP2 knockout and knockdown showing SH3BP2 is necessary for osteoclast differentiation and resorption\",\n      \"pmids\": [\"22153068\", \"21448930\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Structural basis of the tankyrase–SH3BP2 interaction at atomic resolution was not reported in this entry\",\n        \"Whether tankyrase inhibitors phenocopy cherubism in bone was untested at this point\"\n      ]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identification of PARP1 as a transcriptional regulator of SH3BP2 expression added a layer of transcriptional control, showing that PARP1 binds the SH3BP2 promoter and is required for its expression in bone marrow macrophages.\",\n      \"evidence\": \"Promoter deletion, EMSA, ChIP, Parp1 knockout mouse BMMs, luciferase reporter\",\n      \"pmids\": [\"22820184\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether PARP1-dependent transcription is regulated during osteoclast differentiation was not addressed\",\n        \"Relationship between transcriptional and post-translational (tankyrase) regulation was unexplored\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrating that SH3BP2 gain-of-function enables RANKL-independent, TNF-α-driven osteoclastogenesis through SYK–PLCγ2–NFATc1, and that SH3BP2 gain-of-function worsens inflammatory arthritis in a myeloid-specific manner, unified the TNF-α and RANKL signaling arms of SH3BP2 biology.\",\n      \"evidence\": \"Knock-in BMM assays with TNF-α, phospho-SYK/PLCγ2, NFATc1 translocation; collagen-induced arthritis model with micro-CT and cytokine profiling\",\n      \"pmids\": [\"24916406\", \"25144740\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Direct physical interaction between SH3BP2 and SYK in osteoclasts was not shown by reciprocal co-IP\",\n        \"Therapeutic potential of targeting SH3BP2 or SYK in arthritis was not tested\"\n      ]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Extending SH3BP2 function beyond immune/bone cells, SH3BP2 silencing in GISTs downregulated KIT and PDGFRA via MITF, suppressing tumor growth, revealing SH3BP2 as a regulator of receptor tyrosine kinase expression in cancer.\",\n      \"evidence\": \"siRNA knockdown in GIST cell lines, Western blotting, xenograft model, MITF rescue experiment\",\n      \"pmids\": [\"29885053\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Mechanism by which SH3BP2 regulates MITF expression or stability was not defined\",\n        \"Whether SH3BP2's adaptor function or a transcription-coupled mechanism is responsible was unclear\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Conditional myeloid-specific SH3BP2 and SYK deletion established that the SH3BP2–SYK axis specifically controls osteoclast resorptive activity rather than osteoclast differentiation per se, while pharmacological tankyrase inhibition in vivo confirmed that SH3BP2 protein stabilization drives bone loss.\",\n      \"evidence\": \"LysM-Cre conditional knockout in periodontitis model, SYK inhibitor, micro-CT; tankyrase inhibitor treatment in mice with SH3BP2 protein measurement\",\n      \"pmids\": [\"31613396\", \"30813388\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"How SH3BP2–SYK selectively controls resorption without affecting differentiation was mechanistically unexplained\",\n        \"Whether tankyrase inhibitor bone effects are entirely SH3BP2-dependent or involve other tankyrase substrates was not resolved\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"SH3BP2 loss-of-function ameliorated lupus in Fas-mutant mice by suppressing dendritic cell differentiation, expanding the known immune cell types regulated by SH3BP2 beyond macrophages and osteoclasts.\",\n      \"evidence\": \"Sh3bp2-/- × Fas lupus mouse, flow cytometry of dendritic cells, in vitro DC differentiation, renal histology\",\n      \"pmids\": [\"33920631\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Signaling pathway by which SH3BP2 controls DC differentiation was not identified\",\n        \"Whether SH3BP2's role in DCs is cell-autonomous was not fully resolved\"\n      ]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"SH3BP2 was shown to form a PLCγ2–VAV2 signalosome in human podocytes driving glomerular disease, to regulate microglial JAK/STAT signaling in neuroinflammation, and to promote neuromuscular junction AChR clustering via phase separation with the dystrophin-glycoprotein complex, greatly expanding SH3BP2's functional repertoire beyond myeloid/bone biology.\",\n      \"evidence\": \"Co-IP of SH3BP2–PLCγ2–VAV2 in podocytes with KI mouse albuminuria phenotype; shSH3BP2 in SCI rats and BV2 microglia with phospho-JAK/STAT; muscle-specific conditional KO with NMJ imaging, phase separation assay, electrophysiology (preprint)\",\n      \"pmids\": [\"38127456\", \"39546158\", \"bio_10.1101_2024.05.23.595491\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Podocyte signalosome composition beyond PLCγ2 and VAV2 is undefined\",\n        \"JAK/STAT pathway regulation by SH3BP2 lacks biochemical mechanism\",\n        \"Phase separation at the NMJ is from a preprint and awaits peer review\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How SH3BP2 physically connects to SYK and PLCγ at the structural level, how cherubism mutations alter signalosome assembly beyond protein stabilization, and whether therapeutic targeting of the tankyrase–SH3BP2 axis can treat cherubism or inflammatory bone disease remain open questions.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No high-resolution structure of SH3BP2 in complex with SYK, PLCγ, or tankyrase has been reported\",\n        \"Whether SH3BP2 phase separation is a general mechanism across cell types is untested\",\n        \"Therapeutic validation of SH3BP2 pathway inhibition in cherubism patients is absent\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [1, 4, 18, 20]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 4]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [20, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 10, 11, 13, 16]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [1, 4, 5, 10, 19]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [6, 7, 20]}\n    ],\n    \"complexes\": [\n      \"SH3BP2–PLCγ2–VAV2 signalosome\"\n    ],\n    \"partners\": [\n      \"SYK\",\n      \"PLCG1\",\n      \"PLCG2\",\n      \"VAV2\",\n      \"TNKS\",\n      \"YWHAB\",\n      \"MITF\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}